Fast Five Quiz: Managing Progression of Relapsing-Remitting Multiple Sclerosis

Christopher Luzzio, MD; Kerstin Hellwig, MD

Disclosures

July 01, 2022

For patients with a highly active disease course or evidence of a high degree of inflammatory activity, a higher-efficacy DMT should be used.

Prompt identification of these patients allows for earlier consideration of more aggressive therapeutic strategies that have the greatest potential for impact on long-term outcomes.

Approved monoclonal antibody therapies (alemtuzumab, ocrelizumab, and natalizumab) are considered high-efficacy therapies appropriate for patients with moderate to severe RRMS. Among approved oral therapies, most experts consider fingolimod to exhibit higher efficacy compared with dimethyl fumarate or teriflunomide.

Ultimately, the choice of a high-efficacy DMT should point to the agent most likely to safely control the disease for an individual patient, with consideration given to mode of administration. Given the current number of DMT drugs, more individualized therapy is possible.

Learn more about treatment and management.

Editor's Recommendations

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.

processing....